Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

To join this study, people need to be at least 18 years old and willing to follow all study instructions. You must have Non-Small Cell Lung Cancer that has spread to your brain, and your doctor must be planning for you to receive immune checkpoint inhibitor medicines as part of your treatment. The brain tumors need to be a certain size to be included in the study. You also need to be generally well enough to endure the study procedures, as assessed by your doctor.

There are also some reasons why you might not be able to join. For instance, if you have signs of bleeding in your brain, or if you have certain medical conditions that increase your risk of bleeding. If you are pregnant or planning to become pregnant during the study, you cannot take part. Additionally, if you are taking certain medications that can increase bleeding, or have active infections like Hepatitis B or C, you would not be able to join the study.

If you join this study, you'll be randomly assigned to one of two groups: either you'll receive the Exablate procedure along with your standard immune checkpoint inhibitor treatment, or you'll receive only your standard immune checkpoint inhibitor treatment. The immune checkpoint inhibitor treatment will usually be given every three weeks for up to six cycles, as prescribed by your doctor. The study will involve regular visits to track your health and how your brain tumors are responding. There will be follow-up appointments for at least six months. The total duration of your participation could vary depending on your treatment plan and how long you remain in the study.